trending Market Intelligence /marketintelligence/en/news-insights/trending/l1esrck1wjasmvh6g10dgq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA approves Mylan's generic ADHD drug

Power Forecast Briefing: Tight Reserves to Benefit Conventional Gas Generation versus Renewable Energy

State of the Market: Mining Q2-2019

Mining Exploration Insights

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency


US FDA approves Mylan's generic ADHD drug

Mylan NV received final approval from the U.S. FDA for its abbreviated new drug application for Methylphenidate Hydrochloride extended-release tablets, a generic version of Janssen Pharmaceuticals Inc.'s Concerta tablets.

The product is intended for the treatment of attention deficit hyperactivity disorder.

Mylan also launched the generic product in the U.S. Methylphenidate Hydrochloride extended-release tablets had sales of about $1.59 billion in the U.S. for the 12 months ending Oct. 31, according to data from IMS Health.